Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Infectious disease R&D Pipeline

Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Programs 1,112

Quick answer

Infectious disease: NovaPharmaNews indexes 1,112 infectious disease clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Top sponsors

Pipeline programs

Page 8 of 24

  1. APL-9

    Apellis Europe B.V.

    COVID

    phase 2 small molecule completed

    1 trial

  2. ARB-001467

    Arbutus Biopharma Corp

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  3. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  4. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  5. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  6. ARC-520 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  7. ARC-520 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  8. ARCT-021 single dose priming

    Arcturus Therapeutics Holdings

    Covid19

    phase 2 mab terminated

    1 trial

  9. ARCT-165

    Arcturus Therapeutics Holdings

    COVID-19

    phase 2 mab completed

    1 trial

  10. ARO-HBV

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule completed

    1 trial

  11. ARO-HSD Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  12. ASC22

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial

  13. AT-527

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  14. AT-527

    Atea Pharmaceuticals

    COVID-19

    phase 2 small molecule terminated

    2 trials

  15. AT-777

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  16. AVI-4065 Injection

    Sarepta Therapeutics

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  17. Alvelestat

    Mereo BioPharma Group plc

    Covid19

    phase 2 small molecule completed

    1 trial

  18. Analogs, Prostaglandin E1

    Vera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  19. Anti-PD-1 antibody

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule active

    1 trial

  20. Antibody UB-421

    United Therapeutics Europe Ltd

    HIV-1 Infection in Adults

    phase 2 small molecule completed

    1 trial

  21. Aprepitant injectable emulsion

    Heron Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  22. BEVACIZUMAB

    Pari Pharma GmbH

    Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.

    phase 2 small molecule active

    1 trial

  23. BMS-955176

    ViiV Healthcare B.V.

    HIV Infections

    phase 2 small molecule terminated

    1 trial

  24. BRII-179

    Vir Biotechnology

    For Treatment of Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  25. BRII-835 (VIR-2218)

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  26. Bacteriophage

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 small molecule terminated

    1 trial

  27. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Urinary Tract Infection Bacterial

    phase 2 mab terminated

    1 trial

  28. Bamlanivimab

    Vir Biotechnology

    COVID-19

    phase 2 small molecule completed

    1 trial

  29. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

    phase 2 other terminated

    1 trial

  30. Behavioral Drug and Risk Counseling (BDRC)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Risk Behaviors

    phase 2 other completed

    1 trial

  31. Bemnifosbuvir

    Atea Pharmaceuticals

    Chronic Hepatitis C Virus

    phase 2 small molecule completed

    1 trial

  32. Benznidazole

    BRIGHT MINDS BIOSCIENCES INC.

    Trypanosoma Cruzi Infection

    phase 2 small molecule completed

    1 trial

  33. Bisphosphocin Nu-3

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  34. Bovine colostrum

    Hospital Authority, Hong Kong

    Severe Alcoholic Hepatitis in 'Extremis'- Defined by mDF>54

    phase 2 other completed

    1 trial

  35. Brincidofovir

    Jazz Pharmaceuticals Ireland Limited

    Cytomegalovirus Infection

    phase 2 small molecule completed

    1 trial

  36. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  37. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  38. BufferGel

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 small molecule completed

    1 trial

  39. C3601010

    Pfizer Australia Pty Ltd

    Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection

    phase 2 small molecule active

    1 trial

  40. CAP-1002

    CAPRICOR THERAPEUTICS, INC.

    Covid19

    phase 2 mab completed

    1 trial

  41. CERC-002

    Avalo Therapeutics

    COVID-19 Pneumonia

    phase 2 small molecule completed

    1 trial

  42. CF 102

    Can-Fite BioPharma

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  43. CF102

    Can-Fite BioPharma

    Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  44. CHRONVAC-C®

    INOVIO PHARMACEUTICALS, INC.

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule active

    1 trial

  45. COVAXIN(BBV152)

    Biotech Pharmaceutical Co.,

    Corona Virus Infection

    phase 2 mab completed

    1 trial

  46. COVID-19 Vaccine HIPRA

    Hipra Human Health S.L.

    COVID-19

    phase 2 mab completed

    1 trial

  47. CP101

    Finch Therapeutics Group

    Clostridium Difficile Infection

    phase 2 mab completed

    1 trial

  48. CRCFC-TEICO.SA.2022

    Verona Pharma Ireland Limited

    cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many infectious disease pipeline programs are tracked?

1,112 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.